The Potential Protective Effect of Using Muscle Relaxants During Electroporation Ablation (PFA)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-90
Sponsor4th Military Clinical Hospital with Polyclinic, Poland

About this trial

The study aims to improve the safety of the electroporation ablation (PFA) procedure by using muscle relaxants to reduce skeletal muscle damage during the procedure. It will also assess myocardial damage to improve the procedure's quality and speed up recovery after the procedure.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with requirement for PFA ablation for cardiac indications and ability to provide informed consent for study participation

Disqualifiers

Patients with allergies to the general anaesthetics used, genetic diseases of the neuromuscular plateau - e.g. Duchenne dystrophy, myasthenia gravis - and patients who do not gived informed consent to participate in the study will be excluded from the study.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Propofol

    Drug

    Induction of anaesthesia: * Fentanyl 1-3ug/kg/m.c i.v. * Ketamine 50mg i.v. * Propofol 1.5-2mg/kg/m.c i.v. * Rocuronium 5mg (b.w.\<60kg) 10mg (b.w.\>60kg) i.v. Precurarisation * Chlorucinylcholine 1-1.5mg/kg/m.c i.v. -\> Intubation Application (cycle of 5 pulses with 2000V biphasic alternating current) - during PFA: \- In case of ventilatory distress pPeak \>30 cm H2O ad hoc Propofol 0.25-0.75mg/kg/m.c i.v. Elimination of neuromuscular blockade: \- To exclude residual relaxation after pre-curative: 1mg Atropine i.v. + 0.5mg Neostigmine i.v.

  • Rocuronium

    Drug

    Induction of anaesthesia: * Fentanyl 1-3ug/kg/m.c i.v. * Ketamine 50mg i.v. * Propofol 1.5-2mg/kg/m.c i.v. * Rocuronium 5mg (b.w.\<60kg) 10mg (b.w.\>60kg) i.v. Precurarisation * Chlorucinylcholine 1-1.5mg/kg/m.c i.v. -\> Intubation Application (cycle of 5 pulses with 2000V biphasic alternating current) - during PFA: \- rocuronium 0.1-0.3mg/kg/m.c i.v. For TOF \<2 Abolition of neuromuscular blockade: \- Atropine 1-1.5mg i.v. + 1-3mg Neostigmine i.v. Or Sugammadex 2-4mg/kg/m.c i.v.

Treatment groups

32 Participants
are divided into 2 treatment groups
Group A: Group I (no muscular relaxant)Active comparator 1 intervention
Group B: Group II (muscular relaxant)Active comparator 1 intervention

Trial outcomes

Primary outcomes

1

Baseline laboratory parameters and additional tests

Serum creatinine Serum potassium General morphology evaluation of HGB and PLT values Assessment of QoR-15 Measurement of heart size and mass on TTE ultrasound

Time frame
up to 24 hours before procedure
2

During the procedure (before the start of current application)

Serum myoglobin Serum troponin Serum CPK

Time frame
before the start of current application
3

Endline laboratory parameters and additional tests

Serum myoglobin Serum troponin Serum CPK Serum creatinine Serum potassium Total morphology evaluation of HGB and PLT values

Time frame
12 hours after procedure
4

NRS

numerical pain scale 0-10 points

Time frame
Checked before procedure and every 6 hours for the first 24 hours after the procedure

Secondary outcomes

1

BMI

Body mass index 15-45

Time frame
Before performing procedure

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.